Senderra Rx hires Stephen Lund
FLINT, Mich. — Specialty pharmacy Senderra Rx has hired a former executive at Diplomat, Rite Aid and Perry Drug Store as its EVP strategic initiatives.
The Richardson, Texas-based company announced Thursday the hiring of Stephen Lund, who immediately before worked as a specialty pharmacy industry consultant.
"Steve brings a lifelong pharmacy career to Sendera Rx, with a strong expertise in specialty pharmacy," Senderra Rx chairman Win Purifoy said. "We are excited to have him on our team and help us fuel our future growth in this dynamic specialty pharmacy market."
The company also hired Kathy Lenzi as director of patient services. Lenzi previously worked as manager of contract management at Diplomat.
Endo bid for Canadian drug maker clears regulatory hurdle
MALVERN, Pa. — Endo announced Thursday that regulatory waiting periods in the United States and Canada related to its plans to acquire a Montreal-based drug maker have been terminated.
Endo said that the waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act and a similar period required under the Canadian Competition Act had been terminated, allowing it to move ahead with its purchase of Paladin Labs. The plan remains subject to additional regulatory and other conditions, including approval by the companies’ shareholders and an approval by the Superior Court of Quebec.
Endo said last month it would acquire Paladin Labs for $1.6 billion. Paladin specializes in treatments for attention deficity hyperactivity disorder, urology and other indications. The company will continue to operate under its present name after the acquisition is complete.
Diplomat becomes distributor of recently approved cancer drug
FLINT, Mich. — Diplomat has become a distributor of a new cancer drug made by Genentech, Diplomat said Thursday.
The specialty pharmacy company said it had received a distribution contract for Gazyva (obinutuzumab) for chronic lymphocytic leukemia, which received Food and Drug Administration approval on Nov. 1. CLL is a slowly advancing blood and bone marrow disease that, according to the National Cancer Institute, part of the National Institutes of Health, will be diagnosed in 15,680 Americans this year and cause 4,580 deaths.
"We are pleased to partner with Genentech as a specialty pharmacy provider of Gazyva," Diplomat president Gary Kadlec said. "With our extensive clinical and industry experience with new and emerging drug therapies, we are committed to providing Gazyva according to Diplomat’s high standards and industry-leading protocols, enabling patients to obtain the best outcomes possible."
The drug is administered intravenously in conjunction with chlorambucil, a chemotherapy drug also used to treat CLL. The drug’s labeling includes a boxed warning, the highest-level warning a drug can carry, due to the risk of viral reactivation in patients with hepatitis B and the risk of progressive multifocal leukoencephalopathy, or PML, a rare disorder that damages the material covering and protecting nerves in the white matter of the brain.
CORRECTION: A previous version of this story reported that Diplomat had joined a limited-distribution network for Gazyva, based on an erroneous statement in the specialty pharmacy’s press release. Gazyva is an open-distribution drug for which Diplomat has been named a distributor. This version of the story corrects the error.